Compare Abeona Therapeutics Inc (ABEO) vs Kaltura Inc (KLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Kaltura Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Kaltura Inc trades at $1.25 (market cap $193.23M). The key difference: Abeona Therapeutics Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | KLTR | |
|---|---|---|
Market Cap | $373.32M | $193.23M |
Sector | Health | Technology |
52-Week High | $7.23 | $2.01 |
52-Week Low | $4.17 | $1.08 |
Enterprise Value | $228.22M | $175.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Kaltura (KLTR) trades at $1.29, up 2.38% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $180M and narrowing losses, though it remains unprofitable with negative margins. Recent industry recognition and AI product launches highlight strategic positioning in digital experience platforms.
Investment outlook balances operational improvements against persistent profitability challenges. Positive analyst sentiment (44% buy ratings) and strong institutional coverage suggest potential upside if AI initiatives drive growth, but high P/B ratio and negative cash flow pose risks for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
